文献速递治疗药物监测与药物基因组学抗菌药物管理

模型集成用于先验模型引导精准给药的药代动力学模型选择

Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling.
PubMed 文献 · Clin Pharmacokinet · 2024-09-27

该研究基于万古霉素和伊马替尼的群体药代动力学模型,开发并评估了多种模型选择与集成方法,利用治疗药物监测样本进行外部评价,以识别每例患者的最佳模型用于先验剂量个体化。结果显示,基于协变量决策树的模型集成方法在提升患者治疗窗内暴露比例方面表现最优,但需前瞻性验证后方可临床实施。

要点

  • 利用少量TDM样本外部评价可筛选出每例患者的最佳群体药代动力学模型。
  • 决策树集成方法在万古霉素和伊马替尼队列中均显著提高治疗窗内暴露比例。
  • 模型选择与集成可排除性能不佳的模型,但临床实施前需前瞻性验证。

核心结论

  • 利用相对少量TDM样本进行外部评价,可为每例患者识别最佳模型或模型集用于先验剂量个体化。
  • 性能良好的群体药代动力学模型可被识别,同时排除性能不佳的模型。
  • 剂量推荐使万古霉素和伊马替尼更多患者达到治疗范围。

研究设计与样本

  • 研究纳入住院接受连续万古霉素治疗患者134例(26个模型)和门诊接受伊马替尼治疗患者92例(12个模型),基于TDM样本进行外部评价。
  • 比较了四种模型选择方法与标准给药:基于外部验证的最佳模型、无信息模型集成、基于协变量分层外部评价加权方案的模型集成、以及使用决策树协变量选择后集成的模型选择。

主要发现

  • 万古霉素方法开发队列中,最佳模型、无权重、加权和决策树方法的达标比例相对改善分别为-7.0%、2.3%、11.4%和37.0%。
  • 万古霉素验证队列中,上述方法的相对改善分别为23.2%、7.9%、15.6%和77.2%。
  • 伊马替尼方法开发队列中,相对改善分别为40.7%、50.0%、59.5%和59.5%。
  • 伊马替尼验证队列中,相对改善分别为19.0%、28.5%、38.0%和23.8%。

临床怎么用

  • 临床可借助少量TDM样本外部评价筛选最佳群体药代动力学模型,用于先验剂量个体化。
  • 决策树集成方法在提升治疗窗内暴露比例方面表现较优,但需前瞻性验证后实施。

局限性

  • 研究结论需前瞻性验证后方可临床实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: When utilizing population pharmacokinetic (popPK) models for a priori dosage individualization, selecting the best model is crucial to obtain adequate doses. We developed and evaluated several model-selection and ensembling methods, using external evaluation on the basis of therapeutic drug monitoring (TDM) samples to identify the best (set of) models per patient for a priori dosage individualization. METHODS: PK data and models describing both hospitalized patients (n = 134) receiving continuous vancomycin (26 models) and patients (n = 92) receiving imatinib in an outpatient setting (12 models) are included. Target attainment of four model-selection methods was compared with standard dosing: the best model based on external validation, uninformed model ensembling, model ensembling using a weighting scheme on the basis of covariate-stratified external evaluation, and model selection using covariates in decision trees that were subsequently ensembled. RESULTS: Overall, the use of PK models improved the proportion of patients exposed to concentrations within the therapeutic window for both cohorts. Relative improvement of proportion on target for best model, unweighted, weighted, and decision trees were - 7.0%, 2.3%, 11.4%, and 37.0% (vancomycin method-development); 23.2%, 7.9%, 15.6%, and, 77.2% (vancomycin validation); 40.7%, 50.0%, 59.5%, and 59.5% (imatinib method-development); and 19.0%, 28.5%, 38.0%, and 23.8% (imatinib validation), respectively. CONCLUSIONS: The best (set of) models per patient for a priori dosage individualization can be identified using a relatively small set of TDM samples as external evaluation. Adequately performing popPK models were identified while also excluding poor-performing models. Dose recommendations resulted in more patients within the therapeutic range for both vancomycin and imatinib. Prospective validation is necessary before clinical implementation.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Agema BC, Kocher T, Öztürk AB, et al. Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling. Clin Pharmacokinet. 2024. PMID: 39331236. doi:10.1007/s40262-024-01425-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。